USPTO serial 79368313
SARBEVAX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 27, 2024
- Examiner
- FAIRBANKS, RONALD L
- Law office
- PETITIONS OFFICE
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SARBEVAX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lauren K. Tagarao
Lauren K. Tagarao Renner, Otto, Boisselle & Sklar, LLP1621 Euclid AvenueFloor 19Cleveland, OH 44115Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and medical preparations for prevention and treatment of infectious diseases, rare diseases, cancers, neurological disorders, cardiovascular disorders, lymphatic disorders, inflammatory disorders, immunoregulatory disorders, immunological disorders, metabolic disorders, reproductive disorders, autoimmune disorders, respiratory disorders, endocrine system related disorders, nephrological disorders, hepatic disorders, haematological disorders, pulmonary disorders, gene or protein regulatory disorders, epigenetic disorders, gastro-intestinal disorders, disorders of the ear, nose and throat, muscular disorders, skeletal disorders, musculo-skeletal disorders, genetic disorders, oral and dental disorders, psychological disorders, psychiatric disorders, neonatal and natal disorders, ageing, ageing associated disorders, skin disorders, ophthalmic disorders, protein deficiency disorders, vitamin deficiency disorders, obstetric and gynaecological disorders, sexual health related disorders, allergic disorders, obesity or obesity related conditions, injuries, wounds, wound-healing conditions, sleep disorders, fatigue disorders, venom or toxin related conditions, addiction and addiction related conditions, and drug overdose; pharmaceuticals, medical and veterinary preparations for prevention and treatment of infectious diseases, rare diseases, cancers, neurological disorders, cardiovascular disorders, lymphatic disorders, inflammatory disorders, immunoregulatory disorders, immunological disorders, metabolic disorders, reproductive disorders, autoimmune disorders, respiratory disorders, endocrine system related disorders, nephrological disorders, hepatic disorders, haematological disorders, pulmonary disorders, gene or protein regulatory disorders, epigenetic disorders, gastro-intestinal disorders, disorders of the ear, nose and throat, muscular disorders, skeletal disorders, musculo-skeletal disorders, genetic disorders, oral and dental disorders, psychological disorders, psychiatric disorders, neonatal and natal disorders, ageing, ageing associated disorders, skin disorders, ophthalmic disorders, protein deficiency disorders, vitamin deficiency disorders, obstetric and gynaecological disorders, sexual health related disorders, allergic disorders, obesity or obesity related conditions, injuries, wounds, wound-healing conditions, sleep disorders, fatigue disorders, venom or toxin related conditions, addiction and addiction related conditions, and drug overdose; biological preparations for medical purposes, for prevention and treatment of infectious diseases, rare diseases, cancers, neurological disorders, cardiovascular disorders, lymphatic disorders, inflammatory disorders, immunoregulatory disorders, immunological disorders, metabolic disorders, reproductive disorders, autoimmune disorders, respiratory disorders, endocrine system related disorders, nephrological disorders, hepatic disorders, haematological disorders, pulmonary disorders, gene or protein regulatory disorders, epigenetic disorders, gastro-intestinal disorders, disorders of the ear, nose and throat, muscular disorders, skeletal disorders, musculo-skeletal disorders, genetic disorders, oral and dental disorders, psychological disorders, psychiatric disorders, neonatal and natal disorders, ageing, ageing associated disorders, skin disorders, ophthalmic disorders, protein deficiency disorders, vitamin deficiency disorders, obstetric and gynaecological disorders, sexual health related disorders, allergic disorders, obesity or obesity related conditions, injuries, wounds, wound-healing conditions, sleep disorders, fatigue disorders, venom or toxin related conditions, addiction and addiction related conditions, and drug overdose; biological preparations for veterinary purposes, for prevention and treatment of infectious diseases, rare diseases, cancers, neurological disorders, cardiovascular disorders, lymphatic disorders, inflammatory disorders, immunoregulatory disorders, immunological disorders, metabolic disorders, reproductive disorders, autoimmune disorders, respiratory disorders, endocrine system related disorders, nephrological disorders, hepatic disorders, haematological disorders, pulmonary disorders, gene or protein regulatory disorders, epigenetic disorders, gastro-intestinal disorders, disorders of the ear, nose and throat, muscular disorders, skeletal disorders, musculo-skeletal disorders, genetic disorders, oral and dental disorders, psychological disorders, psychiatric disorders, neonatal and natal disorders, ageing, ageing associated disorders, skin disorders, ophthalmic disorders, protein deficiency disorders, vitamin deficiency disorders, obstetric and gynaecological disorders, sexual health related disorders, allergic disorders, obesity or obesity related conditions, injuries, wounds, wound-healing conditions, sleep disorders, fatigue disorders, venom or toxin related conditions, addiction and addiction related conditions, and drug overdose; chemical preparations for medical purposes for prevention and treatment of infectious diseases, rare diseases, cancers, neurological disorders, cardiovascular disorders, lymphatic disorders, inflammatory disorders, immunoregulatory disorders, immunological disorders, metabolic disorders, reproductive disorders, autoimmune disorders, respiratory disorders, endocrine system related disorders, nephrological disorders, hepatic disorders, haematological disorders, pulmonary disorders, gene or protein regulatory disorders, epigenetic disorders, gastro-intestinal disorders, disorders of the ear, nose and throat, muscular disorders, skeletal disorders, musculo-skeletal disorders, genetic disorders, oral and dental disorders, psychological disorders, psychiatric disorders, neonatal and natal disorders, ageing, ageing associated disorders, skin disorders, ophthalmic disorders, protein deficiency disorders, vitamin deficiency disorders, obstetric and gynaecological disorders, sexual health related disorders, allergic disorders, obesity or obesity related conditions, injuries, wounds, wound-healing conditions, sleep disorders, fatigue disorders, venom or toxin related conditions, addiction and addiction related conditions, and drug overdose; chemical preparations for pharmaceutical purposes for prevention and treatment of infectious diseases, rare diseases, cancers, neurological disorders, cardiovascular disorders, lymphatic disorders, inflammatory disorders, immunoregulatory disorders, immunological disorders, metabolic disorders, reproductive disorders, autoimmune disorders, respiratory disorders, endocrine system related disorders, nephrological disorders, hepatic disorders, haematological disorders, pulmonary disorders, gene or protein regulatory disorders, epigenetic disorders, gastro-intestinal disorders, disorders of the ear, nose and throat, muscular disorders, skeletal disorders, musculo-skeletal disorders, genetic disorders, oral and dental disorders, psychological disorders, psychiatric disorders, neonatal and natal disorders, ageing, ageing associated disorders, skin disorders, ophthalmic disorders, protein deficiency disorders, vitamin deficiency disorders, obstetric and gynaecological disorders, sexual health related disorders, allergic disorders, obesity or obesity related conditions, injuries, wounds, wound-healing conditions, sleep disorders, fatigue disorders, venom or toxin related conditions, addiction and addiction related conditions, and drug overdose; diagnostic preparations for medical purposes for prevention and treatment of infectious diseases, rare diseases, cancers, neurological disorders, cardiovascular disorders, lymphatic disorders, inflammatory disorders, immunoregulatory disorders, immunological disorders, metabolic disorders, reproductive disorders, autoimmune disorders, respiratory disorders, endocrine system related disorders, nephrological disorders, hepatic disorders, haematological disorders, pulmonary disorders, gene or protein regulatory disorders, epigenetic disorders, gastro-intestinal disorders, disorders of the ear, nose and throat, muscular disorders, skeletal disorders, musculo-skeletal disorders, genetic disorders, oral and dental disorders, psychological disorders, psychiatric disorders, neonatal and natal disorders, ageing, ageing associated disorders, skin disorders, ophthalmic disorders, protein deficiency disorders, vitamin deficiency disorders, obstetric and gynaecological disorders, sexual health related disorders, allergic disorders, obesity or obesity related conditions, injuries, wounds, wound-healing conditions, sleep disorders, fatigue disorders, venom or toxin related conditions, addiction and addiction related conditions, and drug overdose; drugs for medical purposes for prevention and treatment of infectious diseases, rare diseases, cancers, neurological disorders, cardiovascular disorders, lymphatic disorders, inflammatory disorders, immunoregulatory disorders, immunological disorders, metabolic disorders, reproductive disorders, autoimmune disorders, respiratory disorders, endocrine system related disorders, nephrological disorders, hepatic disorders, haematological disorders, pulmonary disorders, gene or protein regulatory disorders, epigenetic disorders, gastro-intestinal disorders, disorders of the ear, nose and throat, muscular disorders, skeletal disorders, musculo-skeletal disorders, genetic disorders, oral and dental disorders, psychological disorders, psychiatric disorders, neonatal and natal disorders, ageing, ageing associated disorders, skin disorders, ophthalmic disorders, protein deficiency disorders, vitamin deficiency disorders, obstetric and gynaecological disorders, sexual health related disorders, allergic disorders, obesity or obesity related conditions, injuries, wounds, wound-healing conditions, sleep disorders, fatigue disorders, venom or toxin related conditions, addiction and addiction related conditions, and drug overdose; medicines for human purposes for prevention and treatment of infectious diseases, rare diseases, cancers, neurological disorders, cardiovascular disorders, lymphatic disorders, inflammatory disorders, immunoregulatory disorders, immunological disorders, metabolic disorders, reproductive disorders, autoimmune disorders, respiratory disorders, endocrine system related disorders, nephrological disorders, hepatic disorders, haematological disorders, pulmonary disorders, gene or protein regulatory disorders, epigenetic disorders, gastro-intestinal disorders, disorders of the ear, nose and throat, muscular disorders, skeletal disorders, musculo-skeletal disorders, genetic disorders, oral and dental disorders, psychological disorders, psychiatric disorders, neonatal and natal disorders, ageing, ageing associated disorders, skin disorders, ophthalmic disorders, protein deficiency disorders, vitamin deficiency disorders, obstetric and gynaecological disorders, sexual health related disorders, allergic disorders, obesity or obesity related conditions, injuries, wounds, wound-healing conditions, sleep disorders, fatigue disorders, venom or toxin related conditions, addiction and addiction related conditions, and drug overdose; vaccines for prevention and treatment of infectious diseases, rare diseases, cancers, neurological disorders, cardiovascular disorders, lymphatic disorders, inflammatory disorders, immunoregulatory disorders, immunological disorders, metabolic disorders, reproductive disorders, autoimmune disorders, respiratory disorders, endocrine system related disorders, nephrological disorders, hepatic disorders, haematological disorders, pulmonary disorders, gene or protein regulatory disorders, epigenetic disorders, gastro-intestinal disorders, disorders of the ear, nose and throat, muscular disorders, skeletal disorders, musculo-skeletal disorders, genetic disorders, oral and dental disorders, psychological disorders, psychiatric disorders, neonatal and natal disorders, ageing, ageing associated disorders, skin disorders, ophthalmic disorders, protein deficiency disorders, vitamin deficiency disorders, obstetric and gynaecological disorders, sexual health related disorders, allergic disorders, obesity or obesity related conditions, injuries, wounds, wound-healing conditions, sleep disorders, fatigue disorders, venom or toxin related conditions, addiction and addiction related conditions, and drug overdose; medical, biological and pharmaceutical preparations for scientific, research, medical, or pharmaceutical use, namely, preparations for prevention and treatment of infectious diseases, rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, immunological disorders, metabolic disorders, and reproductive disorders; medical, biological and pharmaceutical preparations containing nucleic acids or proteins for the prevention and treatment of infectious diseases, rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, immunological disorders, metabolic disorders, and reproductive disorders; a full line of pharmaceuticals, vaccines, medicines, biologics, biotherapeutics, biosimilars and therapeutic for prevention and treatment of infectious diseases, rare diseases, cancers, neurological disorders, cardiovascular disorders, lymphatic disorders, inflammatory disorders, immunoregulatory disorders, immunological disorders, metabolic disorders, reproductive disorders, autoimmune disorders, respiratory disorders, endocrine system related disorders, nephrological disorders, hepatic disorders, haematological disorders, pulmonary disorders, gene or protein regulatory disorders, epigenetic disorders, gastro-intestinal disorders, disorders of the ear, nose and throat, muscular disorders, skeletal disorders, musculo-skeletal disorders, genetic disorders, oral and dental disorders, psychological disorders, psychiatric disorders, neonatal and natal disorders, ageing, ageing associated disorders, skin disorders, ophthalmic disorders, protein deficiency disorders, vitamin deficiency disorders, obstetric and gynaecological disorders, sexual health related disorders, allergic disorders, obesity or obesity related conditions, injuries, wounds, wound-healing conditions, sleep disorders, fatigue disorders, venom or toxin related conditions, addiction and addiction related conditions, and drug overdose. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 8, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 14, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 13, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 27, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 4, 2024 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Nov 4, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 4, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 4, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 27, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 27, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 9, 2024 | CHPN | POST PUBLICATION AMENDMENT – NOT ENTERED | — |
| Jul 1, 2024 | APET | ASSIGNED TO PETITION STAFF | — |
| Jun 12, 2024 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Jun 11, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 11, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 22, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 9, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 18, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 18, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 18, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 11, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 21, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 21, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 2, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 1, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 24, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| May 2, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 28, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 27, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |